FULC - CIK 0001680581
The table below shows Fulcrum Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$60.06M | -$2.22M | -$90.97M | -$97.05M | -$78.48M | -$53.66M |
| Capital expenditure | $314.00K | $278.00K | $508.00K | $1.96M | $1.71M | $1.34M |
| Investing cash flow | $30.72M | $32.23M | -$36.69M | $12.41M | -$129.67M | -$57.14M |
| Dividends paid | - | - | - | - | - |
Fulcrum Therapeutics, Inc. reported operating cash flow of -$60.06M for fiscal year 2025. That is down 2608.1% from -$2.22M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$22.56M (FY 2018) to -$60.06M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $168.67M | $2.75M | $118.12M | $84.32M | $186.51M | $71.13M |